The estimated Net Worth of David Leslie Szekeres is at least $782 Thousand dollars as of 13 July 2023. Mr Szekeres owns over 5,814 units of Heron Therapeutics Inc stock worth over $64,736 and over the last 10 years he sold HRTX stock worth over $70,206. In addition, he makes $647,124 as Exec. VP & COO at Heron Therapeutics Inc.
Mr has made over 12 trades of the Heron Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,814 units of HRTX stock worth $10,523 on 13 July 2023.
The largest trade he's ever made was exercising 5,814 units of Heron Therapeutics Inc stock on 13 July 2023 worth over $10,523. On average, Mr trades about 3,079 units every 57 days since 2014. As of 13 July 2023 he still owns at least 35,766 units of Heron Therapeutics Inc stock.
You can see the complete history of Mr Szekeres stock trades at the bottom of the page.
David L. Szekeres is the Exec. VP & COO at Heron Therapeutics Inc.
As the Exec. VP & COO of Heron Therapeutics Inc, the total compensation of Mr Szekeres at Heron Therapeutics Inc is $647,124. There are 6 executives at Heron Therapeutics Inc getting paid more, with Barry Quart having the highest compensation of $5,870,480.
Mr Szekeres is 47, he's been the Exec. VP & COO of Heron Therapeutics Inc since . There are 18 older and 3 younger executives at Heron Therapeutics Inc. The oldest executive at Heron Therapeutics Inc is Dr. Barry D. Quart, 64, who is the Chairman & CEO.
David's mailing address filed with the SEC is 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over $96,663,574 worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth $56,275,132 . The most active insiders traders include Kevin Ctang Capital Managem..., Adam Morgan, and Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $176,989. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth $24,973.
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Heron Therapeutics Inc executives and other stock owners filed with the SEC include: